AR125831A2 - Anticuerpos de quimiocina pan-elr⁺ cxc - Google Patents

Anticuerpos de quimiocina pan-elr⁺ cxc

Info

Publication number
AR125831A2
AR125831A2 ARP220101240A ARP220101240A AR125831A2 AR 125831 A2 AR125831 A2 AR 125831A2 AR P220101240 A ARP220101240 A AR P220101240A AR P220101240 A ARP220101240 A AR P220101240A AR 125831 A2 AR125831 A2 AR 125831A2
Authority
AR
Argentina
Prior art keywords
antibodies
elr
cxc
chemocine
pan
Prior art date
Application number
ARP220101240A
Other languages
English (en)
Inventor
Catherine Brautigam Beidler
Jeffrey Streetman Boyles
Kristine Kay Kikly
Beth Ann Strifler
Derrick Ryan Witcher
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR125831A2 publication Critical patent/AR125831A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

Se proveen anticuerpos que específicamente unen siete quimiocinas ELR⁺ CXC humanas. Los anticuerpos de la invención son útiles para el tratamiento de diversas enfermedades inflamatorias / autoinmunes, tal como enfermedad inflamatoria intestinal (IBD), psoriasis en placas, pustulosis palmoplantar; y cáncer, tal como el cáncer renal o cáncer de ovario.
ARP220101240A 2013-03-15 2022-05-10 Anticuerpos de quimiocina pan-elr⁺ cxc AR125831A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361792800P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR125831A2 true AR125831A2 (es) 2023-08-16

Family

ID=50343858

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP140100675A AR094960A1 (es) 2013-03-15 2014-02-28 Anticuerpos de quimiocina pan-elr⁺ cxc
ARP220101240A AR125831A2 (es) 2013-03-15 2022-05-10 Anticuerpos de quimiocina pan-elr⁺ cxc

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP140100675A AR094960A1 (es) 2013-03-15 2014-02-28 Anticuerpos de quimiocina pan-elr⁺ cxc

Country Status (35)

Country Link
EP (4) EP4467566A3 (es)
JP (1) JP6105146B2 (es)
KR (1) KR101745230B1 (es)
CN (2) CN105143259B (es)
AP (1) AP2015008731A0 (es)
AR (2) AR094960A1 (es)
AU (1) AU2014237898B2 (es)
CA (1) CA2901468C (es)
CL (1) CL2015002531A1 (es)
CY (1) CY1120459T1 (es)
DK (1) DK2970447T3 (es)
EA (1) EA029965B1 (es)
ES (3) ES2769123T3 (es)
HR (1) HRP20181047T1 (es)
HU (1) HUE038834T2 (es)
IL (2) IL241167B (es)
JO (1) JO3580B1 (es)
LT (1) LT2970447T (es)
MA (1) MA38413A1 (es)
ME (1) ME03094B (es)
MX (1) MX364831B (es)
MY (1) MY171213A (es)
NZ (1) NZ711704A (es)
PE (2) PE20191480A1 (es)
PH (1) PH12015502090B1 (es)
PL (1) PL2970447T3 (es)
PT (1) PT2970447T (es)
RS (1) RS57291B1 (es)
SG (1) SG11201507686TA (es)
SI (1) SI2970447T1 (es)
TN (1) TN2015000377A1 (es)
TR (1) TR201807613T4 (es)
TW (1) TWI612059B (es)
UA (1) UA116008C2 (es)
WO (1) WO2014149733A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10047156B2 (en) * 2013-05-17 2018-08-14 Centre National De La Recherche Scientifique (Cnrs) Anti-CXCL1, CXCL7 and CXCL8 antibodies and their applications
US11485781B2 (en) 2017-08-17 2022-11-01 Massachusetts Institute Of Technology Multiple specificity binders of CXC chemokines
MX2020006171A (es) 2018-01-12 2020-09-03 Bristol Myers Squibb Co Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
KR102049180B1 (ko) * 2018-04-02 2019-11-26 고려대학교 산학협력단 체세포에서 유도 만능 줄기세포로의 역분화 유도용 조성물 및 이를 이용한 역분화 유도방법
TWI737000B (zh) 2018-10-22 2021-08-21 美商美國禮來大藥廠 用於治療化膿性汗腺炎之泛-ｅｌｒ＋ｃｘｃ趨化介素抗體
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
CN113087795B (zh) * 2019-12-23 2025-06-10 上海普铭生物科技有限公司 针对趋化因子cx3cl1的抗体及其应用
CN115335406B (zh) * 2020-02-12 2026-01-30 伊莱利利公司 抗体或抗原-结合片段的结晶
TW202206457A (zh) * 2020-04-24 2022-02-16 美商美國禮來大藥廠 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體
CN112358547A (zh) * 2020-09-30 2021-02-12 浙江大学 抗人cxcl-2单克隆抗体3-d3及其编码基因和应用
WO2023192478A1 (en) 2022-04-01 2023-10-05 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
WO2026060205A1 (en) 2024-09-13 2026-03-19 Eli Lilly And Company PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040091503A1 (en) * 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
WO2007107003A1 (en) * 2006-03-22 2007-09-27 Osteopharm Inc. Markers for the diagnosis, monitoring and prognosis of osteoporosis and for assessing the risk for osteoporosis and for osteoporotic fractures
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
PE20090993A1 (es) * 2007-08-29 2009-07-08 Sanofi Aventis Anticuerpos anti-cxcr5 humanizados y derivados de los mismos
GB0806812D0 (en) * 2008-04-15 2008-05-14 Univ Leuven Kath Citrullinated cytokines
EA201071300A1 (ru) * 2008-05-14 2011-06-30 Эли Лилли Энд Компани Антитела к cxcr4
WO2011025962A1 (en) * 2009-08-28 2011-03-03 Dan Allison Antikine antibodies that bind to multiple cc chemokines
JP2011097867A (ja) * 2009-11-05 2011-05-19 Kurume Univ 脊柱靱帯骨化症のマーカーペプチド
JP2013518606A (ja) * 2010-02-09 2013-05-23 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規使用
EP2844290A4 (en) * 2012-05-01 2015-12-16 Glaxosmithkline Llc NOVEL ANTIBODIES

Also Published As

Publication number Publication date
EP4467566A2 (en) 2024-11-27
EP3348569A1 (en) 2018-07-18
IL241167A0 (en) 2015-11-30
CN109134652A (zh) 2019-01-04
JP2016512026A (ja) 2016-04-25
EP3608336B1 (en) 2024-10-02
SG11201507686TA (en) 2015-10-29
CA2901468C (en) 2018-02-20
IL241167B (en) 2019-10-31
MX364831B (es) 2019-05-08
PH12015502090B1 (en) 2020-07-08
MY171213A (en) 2019-10-02
PE20151531A1 (es) 2015-10-28
AU2014237898B2 (en) 2016-05-05
CN109134652B (zh) 2022-05-24
IL269387A (en) 2019-11-28
JP6105146B2 (ja) 2017-03-29
CN105143259B (zh) 2018-09-21
WO2014149733A1 (en) 2014-09-25
HK1212714A1 (en) 2016-06-17
CY1120459T1 (el) 2019-07-10
MX2015013053A (es) 2016-05-18
IL269387B (en) 2021-05-31
PE20191480A1 (es) 2019-10-18
TR201807613T4 (tr) 2018-06-21
BR112015020174A2 (pt) 2017-08-29
AU2014237898A1 (en) 2015-08-20
EP2970447B1 (en) 2018-05-16
EP4467566A3 (en) 2025-04-23
KR20150119155A (ko) 2015-10-23
CL2015002531A1 (es) 2016-06-17
LT2970447T (lt) 2018-07-25
EP3348569B1 (en) 2019-11-27
HRP20181047T1 (hr) 2018-08-24
CA2901468A1 (en) 2014-09-25
EA201591514A1 (ru) 2016-03-31
AP2015008731A0 (en) 2015-09-30
ES2769123T3 (es) 2020-06-24
EP3608336A1 (en) 2020-02-12
PT2970447T (pt) 2018-08-07
EP2970447A1 (en) 2016-01-20
TWI612059B (zh) 2018-01-21
PL2970447T3 (pl) 2018-10-31
SI2970447T1 (en) 2018-06-29
RS57291B1 (sr) 2018-08-31
TW201520226A (zh) 2015-06-01
PH12015502090A1 (en) 2016-01-18
ES2675404T3 (es) 2018-07-11
KR101745230B1 (ko) 2017-06-08
DK2970447T3 (en) 2018-06-18
MA38413A1 (fr) 2017-10-31
CN105143259A (zh) 2015-12-09
ES2993153T3 (en) 2024-12-23
HUE038834T2 (hu) 2018-11-28
NZ711704A (en) 2019-12-20
TN2015000377A1 (en) 2017-01-03
EA029965B1 (ru) 2018-06-29
AU2014237898A8 (en) 2015-08-27
JO3580B1 (ar) 2020-07-05
UA116008C2 (uk) 2018-01-25
ME03094B (me) 2019-01-20
AR094960A1 (es) 2015-09-09

Similar Documents

Publication Publication Date Title
PE20151531A1 (es) ANTICUERPOS CONTRA QUIMIOCINAS CXC Pan-ELR+
JOP20200192A1 (ar) أجسام مضادة لـ tigit
CL2017001154A1 (es) Moléculas de unión específicas para cd73 y usos de las mismas
UY40513A (es) Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de esta
MX376808B (es) Anticuerpos anti-b7-h5 y sus usos.
CL2017003024A1 (es) Tratamiento para el cancer a traves de la manipulación de microflora comensal
EA201791485A1 (ru) Анти-cd47-антитела и их применения
CL2017002035A1 (es) Compuestos de dicarboxamida de benzazepinas.
CR20170079A (es) Agentes de unión a cd123 y usos de estos
ECSP17034845A (es) Conjugados de anticuerpo- farmaco
UY36738A (es) Moduladores de tgr5 y métodos de uso de los mismos
UY35399A (es) Conjugados de fármacos con anticuerpos
MX392779B (es) Anticuerpos anti-cd27
MX390931B (es) Inhibidores marcados con 18f mejorados del antígeno prostático específico de membrana (psma) y su uso como agentes de formación de imágenes para el cáncer de próstata.
CL2015002640A1 (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
MX2016009555A (es) Proteinas de union y metodos para utilizarlas.
MX2018005061A (es) Compuestos de interacción con glicanos y métodos de uso.
MX2018013072A (es) Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
PL3622953T3 (pl) Leczenie skojarzone nowotworu
IL272487B (en) Antibodies useful in cancer diagnosis
PE20170192A1 (es) Mutagenesis dirigida al sitio de anticuerpos receptor desencadenante expresado en las meloid tipo 1 (trem-1) para reducir la viscosidad
ECSP14029713A (es) Moléculas de unión il-6
MX2017007381A (es) Miembros de union para homologo del oncogen de fibrosarcoma musculoadoneurotico (c-maf) humano.
MX2018013222A (es) Anticuerpos de interferon beta y usos de los mismos.
EP3376869A4 (en) TREATMENT OF AUTOIMMUNE DISEASE